Pharma Surge

Pharma Surge

🇺🇸·4d agoResearch

Erratum: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors

Publisher

A
ASCO JCO Journal

USA

This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.

Read original

At a glance

Publisher
ASCO JCO Journal
Region
USA
Scope
Research
Published
July 10, 2026

In-platform summary, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Source route

Continue on ascopubs.org

Leave the platform to read the original full article on the publisher site.

Source: ASCO JCO Journal

Scope: Research

Open original article
Erratum: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors | Pharma Surge